New paradigms in hepatitis B management: only diamonds are forever (Q38588187)

4 September 2017

New paradigms in hepatitis B management: only diamonds are forever (English)

1 reference

4 September 2017

Carla S Coffin

1

1 reference

PubMed ID

26377741

4 September 2017

Samuel S Lee

series ordinal

2

1 reference

4 September 2017

15 September 2015

1 reference

4 September 2017

British Medical Bulletin

1 reference

4 September 2017

116

1 reference

4 September 2017

79-91

1 reference

Hepatitis B virus infection--natural history and clinical consequences

4 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Tracing hepatitis B virus to the 16th century in a Korean mummy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Natural history of chronic hepatitis B: phases in a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Antiviral therapies and prospects for a cure of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

New therapeutic perspectives in HBV: when to stop NAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

The role of HBsAg quantification for monitoring natural history and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Classifying hepatitis B virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Strategies to eliminate HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B: future curative strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B virus (HBV) variants fluctuate in paired plasma and peripheral blood mononuclear cells among patient cohorts during different chronic hepatitis B (CHB) disease phases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Early kinetics of innate and adaptive immune responses during hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Strategies to inhibit entry of HBV and HDV into hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

2-amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Virology. Getting rid of a persistent troublemaker to cure hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Virology. Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B virus persistence after recovery from acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV039

21 January 2018

Identifiers

DOI

10.1093/BMB/LDV039

1 reference

4 September 2017

1 reference

PubMed ID

26377741